ID: ALA4756382

Max Phase: Preclinical

Molecular Formula: C23H27FO8

Molecular Weight: 450.46

Molecule Type: Unknown

Representations

Canonical SMILES:  COc1cc(O)c([C@@H]2O[C@H](CO)[C@@](C)(F)[C@H](O)[C@H]2O)cc1Cc1ccc2c(c1)OCCO2

Standard InChI:  InChI=1S/C23H27FO8/c1-23(24)19(11-25)32-21(20(27)22(23)28)14-9-13(17(29-2)10-15(14)26)7-12-3-4-16-18(8-12)31-6-5-30-16/h3-4,8-10,19-22,25-28H,5-7,11H2,1-2H3/t19-,20+,21+,22-,23-/m1/s1

Standard InChI Key:  PSGPXDNCYGGOCU-BMXMUORJSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 450.46

Molecular Weight (Monoisotopic): 450.1690

AlogP: 1.64

#Rotatable Bonds: 5

Polar Surface Area: 117.84

Molecular Species: NEUTRAL

HBA: 8

HBD: 4

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 9.23

CX Basic pKa:

CX LogP: 1.53

CX LogD: 1.53

Aromatic Rings: 2

Heavy Atoms: 32

QED Weighted: 0.54

Np Likeness Score: 1.05

References

1. Xu G,Du F,Kuo GH,Xu JZ,Liang Y,Demarest K,Gaul MD.  (2020)  5,5-Difluoro- and 5-Fluoro-5-methyl-hexose-based C-Glucosides as potent and orally bioavailable SGLT1 and SGLT2 dual inhibitors.,  30  (17): [PMID:32738984] [10.1016/j.bmcl.2020.127387]

Source

Source(1):

• Scientific Literature